ExploraMed Information

ExploraMed's primary mission is to significantly improve the quality of life for patients through fresh paradigms which create value for our customers and shareholders. ExploraMed is a venture-backed medical technology incubation company dedicated to the identification, creation and development of new medical device solutions. ExploraMed creates new ideas which match certain key fundamental criteria and add capital, intellectual property, and expertise in the fields of clinical, engineering, legal, strategic marketing, and financing, while focusing on efficient and timely development. Partnered with New Enterprise Associates and several key business and clinical leaders from the medical technology industry, ExploraMed has the capability to leverage substantial financial and intellectual resources to accelerate the creation and establishment of new medical technologies, procedures and companies. ExploraMed I, founded in 1995, created two medical device companies, EndoMatrix and TransVascular. EndoMatrix was created to develop a novel approach for tissue bulking in incontinence and GI Reflux, and was acquired by C.R. Bard Inc . in 1997. TransVascular was created to develop several novel revascularization technologies including percutaneous coronary and peripheral bypass and cell injection technologies for cardiac regeneration, and was acquired by Medtronic Inc. in 2003. ExploraMed II, founded in 2004, produced two new businesses, Acclarent Inc., and NeoTract Inc. Acclarent the company that created the field of balloon sinuplasty as a treatment for chronic sinusitis and other new technologies in the field of ENT, and was acquired by Johnson and Johnson in 2010. NeoTract, founded in 2005 has developed a novel minimally invasive technology for the treatment of benign prostatic hypertrophy called the UroLift® system. NeoTract is in the commercial growth phase in the United States, Europe and Australia. ExploraMed III, founded in 2006 produced Vibrynt Inc., and Moximed Inc. Vibrynt, focused on the field of obesity, developed their technology through clinical testing and international approvals until 2013 when the assets were sold to several buyers. Moximed is developing a new therapy for osteo-arthitis called the Kinespring® system. The Kinespring® system is being commercialized internationally and studied under an IDE in the United States. ExploraMed IV, founded in 2012, has produced Nuelle, Inc. so far. Nuelle is a development stage company focused on consumer wellness products for women's health.